Long-term use of benzodiazepines and Z-drugs (BZRA) remains widespread, despite guidelines recommending short-term use and highlighting the harms. On 1 February 2023, a tapering pilot program was laun
Long-term use of benzodiazepines and Z-drugs (BZRA) remains widespread, despite guidelines recommending short-term use and highlighting the harms. On 1 February 2023, a tapering pilot program was laun
Polypharmacy and potentially inappropriate medications (PIMs) contribute to adverse outcomes. Deprescribing, the supervised withdrawal of PIMs, is a key strategy to reduce these risks. Identifying the
